SHAP ranked age, BMI, and vaginal delivery count as dominant contributors, followed by systolic blood pressure, HbA1c, PIR, ...

Seshadri, MD, speaks on CLL's shift toward fixed-duration, MRD-guided regimens, MRD testing barriers, and open questions on ...

This study analyzes health care resource utilization and costs among patients with colorectal cancer (CRC) and ovarian cancer ...

A narrative review finds specialty pharmacies lack a patient-reported outcome measure built for their workflow, despite ...

Nearly all community oncology practices surveyed by the Community Oncology Alliance (COA) are now administering bispecific antibody therapy in-office, but reimbursement gaps and hospital coordination ...

Although cancer has long been the leading cost driver for employer-sponsored health plans, employers are weighing far more than spending when they evaluate cancer care, according to Karen van Caulil, ...

UVA implementation data showed injection-related reactions needing active management in 0.5% of subcutaneous administrations versus 37% with intravenous dosing, contributing $100.27 lower per-visit ...

Quality & Value Study findings discussed in part 1, Stephen "Fred" Divers, MD, explained how the data reshape the narrative around community oncology's sustainability and value, along with how the ...

Clearing hepatitis C sharply reduces liver cancer risk without erasing it. Across 23 studies covering 29,395 patients, HCC occurred at 1.54 per 100 person-years after sustained virologic response ...

As the US records its highest number of measles cases in more than 3 decades, parents heading into fall are also navigating a federal overhaul of childhood vaccine guidance. 1. An ...

Cost per day in dermatology was $68.76 for ruxolitinib versus $4.29 for tacrolimus, implying marked budget impact despite non-equivalence as clinical substitutes. Phase 3 efficacy and tolerability ...

Specialty pharmacists hold high-frequency patient touchpoints and medication event data, enabling near–real time insights into adherence, adverse events, and therapy initiation/discontinuation. The ...